DUBLIN--(BUSINESS WIRE)--The "Orphan Drugs Market: Global Industry Analysis, Trends, Market Size and Forecasts up to 2024" report has been added to ResearchAndMarkets.com's offering.
The report predicts the global orphan drugs market to grow with a CAGR of 6.5% over the forecast period of 2018-2024.
The report on global orphan drugs market provides qualitative and quantitative analysis for the period of 2016 to 2024.
These drugs are used to treat the population suffering from the very serious, but rare diseases for which no treatment available. There are around 25 to 30 million people are affected by this diseases in Europe. The awareness about the orphan drug is growing rapidly across the world that further leads to the growing adoption of orphan drug act in the japan, Australia, Europe and others countries to stimulate research and development in the orphan drug.
The orphan drug market segmented as diseases indication, product type, and distribution channels. The segment dieases type is further divided into sub segment including Oncology, Gastrointestinal, Pulmonary, Neurology, Hematology, Cardiovascular, Metabolic disorders, Endocrinology, Infectious diseases and other. The product type segment included Biological and Non-bio logical products and distributed over the channels like hospital pharmacy, retail pharmacy and others.
Economic incentives to encourage drug companies to develop and market medicines for rare disease treatment is the key driving factor in the orphan drug market. The rising occurrence of rare cancer cases, availability of orphan drugs at hospital pharmacy and increasing hospitalization treatment for rare diseases are expected to enhance the growth of orphan drug market over the forecast period. On the other hand, the cost associate with production and R&D is more as compare with other drugs that may hampering the market growth. Moreover, the rising awareness of rare disease among population and increasing investments in R&D is projected to create several opportunities in upcoming years.
North America dominates the market of orphan drugs owing to its highly developed healthcare infrastructure and favorable government regulations. In North America U.S. holds largest market share in this market due to economic incentives and rising awareness about orphan drug.Moreover, the increasing investments to treat and diagnose the rare disease also to facilitate the growth in the orphan drug market.
Key Topics Covered:
1. Preface
2. Executive Summary
3. Global Orphan Drugs Market Overview
4. Orphan drugs market macro indicator analysis
5. Global Orphan Drugs Market by Disease Type
6. Global Orphan Drugs Market by Product Types
7. Global Orphan Drugs Market by Distribution Channel
8. Global Orphan Drugs Market by Region 2018-2024
9. Company profiles and competitive landscape
- Novartis AG
- Pfizer Inc.
- Alexion Pharmaceuticals
- Eisai Co. Ltd.
- Bayer AG
- Biogen Inc
- Eli Lilly and Company
- AstraZeneca plc.
- GlaxoSmithKline
- Johnson & Johnson
For more information about this report visit https://www.researchandmarkets.com/research/wg9ctt/global_orphan?w=4
